雷扎卢达胺：首次批准。
Rezvilutamide: First Approval.
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2023 Feb;83(2):189-193. doi: 10.1007/s40265-022-01831-y.
PMID:36630077
Abstract
Rezvilutamide () is an oral, second-generation androgen receptor antagonist being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of prostate cancer. In June 2022, rezvilutamide was approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumour burden. This article summarizes the milestones in the development of rezvilutamide leading to this first approval for patients with prostate cancer.
摘要
瑞维鲁胺（）是江苏恒瑞医药股份有限公司开发的一种口服第二代雄激素受体拮抗剂，用于治疗前列腺癌。2022 年 6 月，瑞维鲁胺在中国获批用于治疗高肿瘤负担的转移性去势敏感性前列腺癌（mHSPC）患者。本文总结了瑞维鲁胺开发过程中的重要里程碑，最终使其首次获批用于前列腺癌患者。
Zotero 插件